FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeffrey Lieberman

Research Profile

Disorders

Chemicals & Drugs

Activities & Behaviors

Schizophrenic Psychology

Concepts & Ideas

Procedures

Double-Blind Method

Anatomy

Brain

Living Beings

Co-author Network

Publications

TOP 3
L Fredrik Jarskog; Daniel C Javitt; Alayar Kangarlu; Richard Se Keefe; Lawrence S Kegeles; Stephen R Marder; Joseph P McEvoy; Robert P McMahon; Bradley S Peterson; Deanna M Barch; Robert W Buchanan; Tiziano Colibazzi; John G Csernansky; Zhengchao Dong; Ragy R Girgis; Donald C Goff; Michael P Harms; Jeffrey A Lieberman
Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia.
Jeffrey A Lieberman; Anthony C Segreti; Frances Seoane; Jessica S Beaver; Naihua Duan; Geoffrey Dunbar; Ragy R Girgis; David A Hosford
A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia.
Scott A Schobel; Martin A Styner; Iris Asllani; Nashid H Chaudhury; Cheryl M Corcoran; Benjamin P Inbar; Usman A Khan; Jeffrey A Lieberman; Holly Moore; Beatriz Paniagua; Scott A Small
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeffrey Lieberman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: L Fredrik Jarskog; Daniel C Javitt; Alayar Kangarlu; Richard Se Keefe; Lawrence S Kegeles; Stephen R Marder; Joseph P McEvoy; Robert P McMahon; Bradley S Peterson; Deanna M Barch; Robert W Buchanan; Tiziano Colibazzi; John G Csernansky; Zhengchao Dong; Ragy R Girgis; Donald C Goff; Michael P Harms; Jeffrey A Lieberman
Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2013;38(7):1245-52.
2013: Jeffrey A Lieberman; Anthony C Segreti; Frances Seoane; Jessica S Beaver; Naihua Duan; Geoffrey Dunbar; Ragy R Girgis; David A Hosford
A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2013;38(6):968-75.
2013: Scott A Schobel; Martin A Styner; Iris Asllani; Nashid H Chaudhury; Cheryl M Corcoran; Benjamin P Inbar; Usman A Khan; Jeffrey A Lieberman; Holly Moore; Beatriz Paniagua; Scott A Small
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.
Neuron 2013;78(1):81-93.
2013: J J Crowley; A C Hawes; C E Hilliard; Y Kim; L R Lewis; Jeffrey A Lieberman; M B Morgan; D M Muzny; A Sabo; Patrick F Sullivan; D A Wheeler; R A Gibbs
Deep resequencing and association analysis of schizophrenia candidate genes.
Molecular psychiatry 2013;18(2):138-40.
2013: Robert K McClure; Xiaoyan Shi; Martin Styner; Guido Gerig; Sylvain Gouttard; Jeffrey A Lieberman; Eric Maltbie; Hongtu Zhu
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type.
Psychiatry research 2013;211(1):1-10.
2012: S Miyamoto; N Miyake; W W Fleischhacker; L Fredrik Jarskog; Jeffrey A Lieberman
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
Molecular psychiatry 2012;17(12):1206-27.
2012: Jean A Frazier; Anthony J Giuliano; Robert M Hamer; Jacqueline L Johnson; Jeffrey A Lieberman; Jon McClellan; Linmarie Sikich; Benedetto Vitiello; Lauren Yakutis; Eric A Youngstrom; David Breiger; Robert L Findling; Stephen R Hooper
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
Journal of the American Academy of Child and Adolescent Psychiatry 2012;51(5):496-505.
2011: Stephen R Marder; Bita Moghaddam; Eric J Nestler; Bryan Roth; Akira Saw; Edward M Scolnick; Patrick F Sullivan; Daniel R Welnberger; Akira Sawa; Schahram Akbarian; John A Allen; Robert W Buchanan; Brian Campbell; Marc G Caron; P Jeffrey Conn; Susan R George; Mark A Geyer; Jay A Gingrich; Alessandro Guidotti; Stephen J Haggarty; Maria Karayiorgou; John H Krystal; Amanda J Law; Jeffrey A Lieberman; Michelle Solis
Advancing drug discovery for schizophrenia.
Annals of the New York Academy of Sciences 2011;1236():30-43.
2011: Christine E Marx; J C Naylor; Jennifer L Strauss; Jeffrey A Lieberman; Trina B Allen; Daniel W Bradford; Robert M Hamer; Jason D Kilts
Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.
Neuroscience 2011;191():78-90.
2011: Thomas Stroup; Marvin S Swartz; Robert H Hamer; Lisa M LaVange; Jeffrey A Lieberman; Joseph P McEvoy; Abraham M Nussbaum; Diana O Perkins; Kimberly D Ring; Robert A Rosenheck
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
The American journal of psychiatry 2011;168(9):947-56.
2011: T Scott Stroup; Marvin S Swartz; Theo C Manschreck; Joseph P McEvoy; Paul S Appelbaum; Roger A Boshes; Hongbin Gu; Spencer Hays; Richard S E Keefe; Scott Y H Kim; Jeffrey A Lieberman
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.
Schizophrenia research 2011;130(1-3):47-52.
2011: Ragy R Girgis; David B Merrill; Stanislav R Vorel; Min You; Andrei Pikalov; Richard Whitehead; Jeffrey A Lieberman
Aripiprazole versus haloperidol treatment in early-stage schizophrenia.
Journal of psychiatric research 2011;45(6):756-62.
2011: Gholson J Lyon; Anissa Abi-Dargham; Holly Moore; Jeffrey A Lieberman; Jonathan A Javitch; David Sulzer
Presynaptic regulation of dopamine transmission in schizophrenia.
Schizophrenia bulletin 2011;37(1):108-17.
2010: David Kimhy; Philippe Delespaul; Hongshik Ahn; Shengnan Cai; Marina Shikhman; Jeffrey A Lieberman; Dolores Malaspina; Richard P Sloan
Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology.
Schizophrenia bulletin 2010;36(6):1131-9.
2010: Caline S Karam; Jacob S Ballon; Nancy M Bivens; Zachary Freyberg; Ragy R Girgis; José E Lizardi-Ortiz; Sander Markx; Jeffrey A Lieberman; Jonathan A Javitch
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.
Trends in pharmacological sciences 2010;31(8):381-90.
2010: Laura Rodríguez-Murillo; Jeffrey A Lieberman
[A genetic signature for complex psychiatric diseases].
Revista de psiquiatrí́a y salud mental 2010;3(3):75-8.
2010: Thomas I Konneker; James J Crowley; Corey R Quackenbush; Richard S E Keefe; Diana O Perkins; Thomas Stroup; Jeffrey A Lieberman; Edwin J C G van den Oord; Patrick F Sullivan
No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2010;153B(5):1115-7.
2010: Leisa A Glantz; John Gilmore; David H Overstreet; Kayvon Salimi; Jeffrey A Lieberman; L Fredrik Jarskog
Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression.
Schizophrenia research 2010;118(1-3):292-9.
2010: David B Merrill; Ragy R Girgis; Lincoln C Bickford; Stanislav R Vorel; Jeffrey A Lieberman
Teaching trainees to negotiate research collaborations with industry: a mentorship model.
The American journal of psychiatry 2010;167(4):381-6.
2010: Huei-Ting Tsai; Stanley N Caroff; Joseph McEvoy; Jeffrey A Lieberman; Kari E North; Thomas Stroup; Del D Miller; Patrick F Sullivan
A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2010;153B(1):336-40.
2010: Stephen R Hooper; Anthony J Giuliano; Eric A Youngstrom; David Breiger; Linmarie Sikich; Jean A Frazier; Robert L Findling; Jon McClellan; Robert M Hamer; Benedetto Vitiello; Jeffrey A Lieberman
Neurocognition in early-onset schizophrenia and schizoaffective disorders.
Journal of the American Academy of Child and Adolescent Psychiatry 2010;49(1):52-60.
2009: David L Penn; Richard S E Keefe; Sonia M Davis; Piper S Meyer; Diana O Perkins; Diane Losardo; Jeffrey A Lieberman
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
Schizophrenia research 2009;115(1):17-23.
2009: Kayvon Salimi; L Fredrik Jarskog; Jeffrey A Lieberman
Antipsychotic drugs for first-episode schizophrenia: a comparative review.
CNS drugs 2009;23(10):837-55.
2009: E T Cox; L H Brennaman; Karissa L Gable; Robert M Hamer; Leisa A Glantz; Anthony-Samuel LaMantia; Jeffrey A Lieberman; John Gilmore; Patricia F Maness; L Fredrik Jarskog
Developmental regulation of neural cell adhesion molecule in human prefrontal cortex.
Neuroscience 2009;162(1):96-105.
2009: Christine E Marx; Richard S E Keefe; Robert W Buchanan; Robert M Hamer; Jason D Kilts; Daniel W Bradford; Jennifer L Strauss; Jennifer C Naylor; Victoria M Payne; Jeffrey A Lieberman; Adam J Savitz; Linda A Leimone; Lawrence Dunn; Patrizia Porcu; A Leslie Morrow; Lawrence J Shampine
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(8):1885-903.
2009: Jayendra K Patel; Peter F Buckley; Sandra Woolson; Robert M Hamer; Joseph P McEvoy; Diana O Perkins; Jeffrey A Lieberman
Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.
Schizophrenia research 2009;111(1-3):9-16.
2009: Paul M Thompson; George Bartzokis; Kiralee M Hayashi; Andrea D Klunder; Po Lu; Nancy Edwards; Michael S Hong; Michael Yu; Jennifer A Geaga; Arthur W Toga; Cecil Charles; Diana O Perkins; Joseph McEvoy; Robert M Hamer; Mauricio Tohen; Gary D Tollefson; Jeffrey A Lieberman
Time-lapse mapping of cortical changes in schizophrenia with different treatments.
Cerebral cortex (New York, N.Y. : 1991) 2009;19(5):1107-23.
2009: Jeffrey A Lieberman; Kelly Papadakis; John Csernansky; Robert Litman; Jan Volavka; Xinwei Daniel Jia; Allyson Gage
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(5):1322-9.
2009: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Sonia M Davis; Marvin Swartz; Richard S E Keefe; Alexander Miller; Robert A Rosenheck; John K Hsiao
Results of phase 3 of the CATIE schizophrenia trial.
Schizophrenia research 2009;107(1):1-12.
2008: Linmarie Sikich; Jean A Frazier; Jon McClellan; Robert L Findling; Benedetto Vitiello; Louise Ritz; Denisse Ambler; Madeline Puglia; Ann E Maloney; Emily Michael; Sandra De Jong; Karen Slifka; Nancy Noyes; Stefanie Hlastala; Leslie Pierson; Nora K McNamara; Denise DelPorto-Bedoya; Robert Anderson; Robert M Hamer; Jeffrey A Lieberman
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
The American journal of psychiatry 2008;165(11):1420-31.
2008: Thomas M Maynard; Daniel W Meechan; M L Dudevoir; D Gopalakrishna; A Z Peters; C C Heindel; T J Sugimoto; Y Wu; Jeffrey A Lieberman; Anthony-Samuel LaMantia
Mitochondrial localization and function of a subset of 22q11 deletion syndrome candidate genes.
Molecular and cellular neurosciences 2008;39(3):439-51.
2008: James J Crowley; Richard S E Keefe; Diana O Perkins; Thomas Stroup; Jeffrey A Lieberman; Patrick F Sullivan
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2008;147B(7):1298-300.
2008: R R Girgis; J A Javitch; Jeffrey A Lieberman
Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.
Molecular psychiatry 2008;13(10):918-29.
2008: Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
Pharmacological reviews 2008;60(3):358-403.
2008: Jennifer C Naylor; Christine M Hulette; David C Steffens; Lawrence J Shampine; John F Ervin; Victoria M Payne; Mark W Massing; Jason D Kilts; Jennifer L Strauss; Patrick S Calhoun; Rohana P Calnaido; Daniel G Blazer; Jeffrey A Lieberman; Roger D Madison; Christine E Marx
Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage.
The Journal of clinical endocrinology and metabolism 2008;93(8):3173-8.
2008: Jeffrey Swanson; Marvin Swartz; Richard A Van Dorn; Jan Volavka; John Monahan; Thomas Stroup; Joseph P McEvoy; H Ryan Wagner; Eric Elbogen; Jeffrey A Lieberman
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.
The British journal of psychiatry : the journal of mental science 2008;193(1):37-43.
2008: David L Sultzer; Sonia M Davis; Pierre N. Tariot; Karen S Dagerman; Barry D Lebowitz; Constantine G Lyketsos; Robert A Rosenheck; John K Hsiao; Jeffrey A Lieberman; Lon S Schneider
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
The American journal of psychiatry 2008;165(7):844-54.
2008: Marvin Swartz; Thomas Stroup; Joseph P McEvoy; Sonia M Davis; Robert A Rosenheck; Richard S E Keefe; John K Hsiao; Jeffrey A Lieberman
What CATIE found: results from the schizophrenia trial.
Psychiatric services (Washington, D.C.) 2008;59(5):500-6.
2008: Marvin Swartz; H Ryan Wagner; Jeffrey Swanson; Thomas Stroup; Joseph P McEvoy; Frederick W Reimherr; Del D Miller; Mark McGee; Ahsan Khan; Jose M Canive; Sonia M Davis; John K Hsiao; Jeffrey A Lieberman
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Schizophrenia research 2008;100(1-3):39-52.
2008: Rajendra A Morey; Teresa V Mitchell; Seniha Inan; Jeffrey A Lieberman; Aysenil Belger
Neural correlates of automatic and controlled auditory processing in schizophrenia.
The Journal of neuropsychiatry and clinical neurosciences 2008;20(4):419-30.
2008: Diana O Perkins; Hongbin Gu; Peter Weiden; Joseph P McEvoy; Robert M Hamer; Jeffrey A Lieberman
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
The Journal of clinical psychiatry 2008;69(1):106-13.
2007: Leisa A Glantz; John Gilmore; Robert M Hamer; Jeffrey A Lieberman; L Fredrik Jarskog
Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood.
Neuroscience 2007;149(3):582-91.
2007: Jean A Frazier; Jon McClellan; Robert L Findling; Benedetto Vitiello; Robert Anderson; Benjamin Zablotsky; Emily Williams; Nora K McNamara; Joseph A Jackson; Louise Ritz; Stefanie A Hlastala; Leslie Pierson; Jennifer A Varley; Madeline Puglia; Ann E Maloney; Denisse Ambler; Tyehimba Hunt-Harrison; Robert M Hamer; Nancy Noyes; Jeffrey A Lieberman; Linmarie Sikich
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics.
Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(8):979-88.
2007: Jon McClellan; Linmarie Sikich; Robert L Findling; Jean A Frazier; Benedetto Vitiello; Stefanie A Hlastala; Emily Williams; Denisse Ambler; Tyehimba Hunt-Harrison; Ann E Maloney; Louise Ritz; Robert Anderson; Robert M Hamer; Jeffrey A Lieberman
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.
Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(8):969-78.
2007: Richard S E Keefe; John A Sweeney; Hongbin Gu; Robert M Hamer; Diana O Perkins; Joseph P McEvoy; Jeffrey A Lieberman
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
The American journal of psychiatry 2007;164(7):1061-71.
2007: Joseph P McEvoy; Jeffrey A Lieberman; Diana O Perkins; Robert M Hamer; Hongbin Gu; Arthur Lazarus; Dennis Sweitzer; Christina Olexy; Peter Weiden; Stephen D Strakowski
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
The American journal of psychiatry 2007;164(7):1050-60.
2007: Richard S E Keefe; Robert Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; Thomas Stroup; Joseph P McEvoy; Marvin Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Archives of general psychiatry 2007;64(6):633-47.
2007: Jeffrey A Lieberman; Diana O Perkins; L Fredrik Jarskog
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
CNS spectrums 2007;12(3 Suppl 4):1-13; quiz 14.
2007: Marvin Swartz; Diana O Perkins; Thomas Stroup; Sonia M Davis; George Capuano; Robert A Rosenheck; Frederick W Reimherr; Mark F McGee; Richard S E Keefe; Joseph P McEvoy; John K Hsiao; Jeffrey A Lieberman
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
The American journal of psychiatry 2007;164(3):428-36.
2007: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Marvin Swartz; Sonia M Davis; George Capuano; Robert A Rosenheck; Richard S E Keefe; Alexander Miller; Irving Belz; John K Hsiao
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
The American journal of psychiatry 2007;164(3):415-27.
2007: John Gilmore; Weili Lin; Marcel Prastawa; Christopher B Looney; Y Sampath K Vetsa; Rebecca Knickmeyer; Dianne D Evans; J Smith; Robert M Hamer; Jeffrey A Lieberman; Guido Gerig
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2007;27(6):1255-60.
2007: Jeffrey A Lieberman
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.
The Journal of clinical psychiatry 2007;68(2):e04.
2007: L Fredrik Jarskog; Seiya Miyamoto; Jeffrey A Lieberman
Schizophrenia: new pathological insights and therapies.
Annual review of medicine 2007;58():49-61.
2007: L Fredrik Jarskog; John Gilmore; Leisa A Glantz; Karissa L Gable; Thomas T German; Ruth I Tong; Jeffrey A Lieberman
Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2007;32(1):95-102.
2006: Christine E Marx; William T Trost; Lawrence J Shampine; Robert D Stevens; Christine M Hulette; David C Steffens; John F Ervin; Marian I Butterfield; Daniel G Blazer; Mark W Massing; Jeffrey A Lieberman
The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease.
Biological psychiatry 2006;60(12):1287-94.
2006: Odin van der Stelt; Jeffrey A Lieberman; Aysenil Belger
Attentional modulation of early-stage visual processing in schizophrenia.
Brain research 2006;1125(1):194-8.
2006: Daniel W Meechan; Thomas M Maynard; Y Wu; D Gopalakrishna; Jeffrey A Lieberman; Anthony-Samuel LaMantia
Gene dosage in the developing and adult brain in a mouse model of 22q11 deletion syndrome.
Molecular and cellular neurosciences 2006;33(4):412-28.
2006: Gary E Duncan; Sheryl S Moy; Jeffrey A Lieberman; Beverly H Koller
Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction.
Pharmacology, biochemistry, and behavior 2006;85(3):481-91.
2006: Lon S Schneider; Pierre N. Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; Thomas Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
The New England journal of medicine 2006;355(15):1525-38.
2006: Jeffrey A Lieberman
Neurobiology and the natural history of schizophrenia.
The Journal of clinical psychiatry 2006;67(10):e14.
2006: Jeffrey A Lieberman
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
Archives of general psychiatry 2006;63(10):1069-72.
2006: Joseph P McEvoy; Jackie Johnson; Diana O Perkins; Jeffrey A Lieberman; Robert M Hamer; Richard S E Keefe; Mauricio Tohen; Ira D Glick; Tonmoy Sharma
Insight in first-episode psychosis.
Psychological medicine 2006;36(10):1385-93.
2006: L Fredrik Jarskog; Jeffrey A Lieberman
Neuroprotection in schizophrenia.
The Journal of clinical psychiatry 2006;67(9):e09.
2006: Alan I Green; Jeffrey A Lieberman; Robert M Hamer; Ira D Glick; R E Gur; R S Kahn; Joseph P McEvoy; Diana O Perkins; Anthony J Rothschild; Tonmoy Sharma; Mauricio Tohen; S Woolson; R B Zipursky
Olanzapine and haloperidol in first episode psychosis: two-year data.
Schizophrenia research 2006;86(1-3):234-43.
2006: Henry A Nasrallah; Jonathan M Meyer; Donald C Goff; Joseph P McEvoy; Sonia M Davis; Thomas Stroup; Jeffrey A Lieberman
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.
Schizophrenia research 2006;86(1-3):15-22.
2006: Richard S E Keefe; Robert Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; Thomas Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Baseline neurocognitive deficits in the CATIE schizophrenia trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(9):2033-46.
2006: Christine E Marx; Lawrence J Shampine; Rahul T Khisti; William T Trost; Daniel W Bradford; A Chistina Grobin; Mark W Massing; Roger D Madison; Marian I Butterfield; Jeffrey A Lieberman; A Leslie Morrow
Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions.
Pharmacology, biochemistry, and behavior 2006;84(4):609-17.
2006: Christine E Marx; Lawrence J Shampine; Gary E Duncan; Margaret VanDoren; A Chistina Grobin; Mark W Massing; Roger D Madison; Daniel W Bradford; Marian I Butterfield; Jeffrey A Lieberman; A Leslie Morrow
Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?
Pharmacology, biochemistry, and behavior 2006;84(4):598-608.
2006: Thomas M Maynard; Daniel W Meechan; Clifford C Heindel; Amanda Z Peters; Robert M Hamer; Jeffrey A Lieberman; Anthony-Samuel LaMantia
No evidence for parental imprinting of mouse 22q11 gene orthologs.
Mammalian genome : official journal of the International Mammalian Genome Society 2006;17(8):822-32.
2006: Marvin Swartz; H Ryan Wagner; Jeffrey Swanson; Thomas Stroup; Joseph P McEvoy; Mark McGee; Del D Miller; Frederick W Reimherr; Ahsan Khan; Jose M Cañive; Jeffrey A Lieberman
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study.
Psychiatric services (Washington, D.C.) 2006;57(8):1110-6.
2006: Kate X Zhong; Dennis Sweitzer; Robert M Hamer; Jeffrey A Lieberman
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
The Journal of clinical psychiatry 2006;67(7):1093-103.
2006: J H Councill; Eric S. Tucker; Gloria T Haskell; Thomas M Maynard; Daniel W Meechan; Robert M Hamer; Jeffrey A Lieberman; Anthony-Samuel LaMantia
Limited influence of olanzapine on adult forebrain neural precursors in vitro.
Neuroscience 2006;140(1):111-22.
2006: Jeffrey A Lieberman; L Fredrik Jarskog; Dolores Malaspina
Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.
The Journal of clinical psychiatry 2006;67(6):983-90.
2006: Talaignair N Venkatraman; Robert M Hamer; Diana O Perkins; Allen W Song; Jeffrey A Lieberman; R Grant Steen
Single-voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus.
NMR in biomedicine 2006;19(4):484-91.
2006: R Grant Steen; Courtney Mull; Robert McClure; Robert M Hamer; Jeffrey A Lieberman
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies.
The British journal of psychiatry : the journal of mental science 2006;188():510-8.
2006: Samantha S Gizerian; Sheryl S Moy; Jeffrey A Lieberman; A Chistina Grobin
Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity: neurosteroids alter prepulse inhibition and locomotor activity.
Psychopharmacology 2006;186(3):334-42.
2006: Christine E Marx; Robert D Stevens; Lawrence J Shampine; Veska Uzunova; William T Trost; Marian I Butterfield; Mark W Massing; Robert M Hamer; A Leslie Morrow; Jeffrey A Lieberman
Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(6):1249-63.
2006: Jeffrey Swanson; Marvin Swartz; Richard A Van Dorn; Eric Elbogen; H Ryan Wagner; Robert A Rosenheck; Thomas Stroup; Joseph P McEvoy; Jeffrey A Lieberman
A national study of violent behavior in persons with schizophrenia.
Archives of general psychiatry 2006;63(5):490-9.
2006: Jeffrey A Lieberman; Dolores Malaspina; L Fredrik Jarskog
Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.
CNS spectrums 2006;11(4):suppl 1-13; quiz suppl 14-5.
2006: Thomas Stroup; Jeffrey A Lieberman; Joseph P McEvoy; Marvin Swartz; Sonia M Davis; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne B Severe; John K Hsiao
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
The American journal of psychiatry 2006;163(4):611-22.
2006: Joseph P McEvoy; Jeffrey A Lieberman; Thomas Stroup; Sonia M Davis; Herbert Y Meltzer; Robert A Rosenheck; Marvin Swartz; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne B Severe; John K Hsiao
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
The American journal of psychiatry 2006;163(4):600-10.
2006: Marvin Swartz; H Ryan Wagner; Jeffrey Swanson; Thomas Stroup; Joseph P McEvoy; Jose M Canive; Del D Miller; Frederick W Reimherr; Mark McGee; Ahsan Khan; Richard A Van Dorn; Robert A Rosenheck; Jeffrey A Lieberman
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
The Journal of nervous and mental disease 2006;194(3):164-72.
2006: Diana O Perkins; Jacqueline Johnson; Robert M Hamer; Robert B Zipursky; Richard S E Keefe; Franca Centorrhino; Alan I Green; Ira B Glick; Rene S Kahn; Tonmoy Sharma; Mauricio Tohen; Joseph P McEvoy; Peter Weiden; Jeffrey A Lieberman
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
Schizophrenia research 2006;83(1):53-63.
2006: Thomas Stroup; Wayne Alves; Robert M Hamer; Jeffrey A Lieberman
Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.
Nature reviews. Drug discovery 2006;5(2):133-46.
2006: Robert Bilder; Gail Reiter; Jay Bates; Todd Lencz; Philip Szeszko; Robert S Goldman; Delbert Robinson; Jeffrey A Lieberman; John M Kane
Cognitive development in schizophrenia: follow-back from the first episode.
Journal of clinical and experimental neuropsychology 2006;28(2):270-82.
2006: David B Merrill; Susanne E Ahmari; Jean-Marie E Bradford; Jeffrey A Lieberman
Myocarditis during clozapine treatment.
The American journal of psychiatry 2006;163(2):204-8.
2006: Richard S E Keefe; Larry J Seidman; Bruce K Christensen; Robert M Hamer; Tonmoy Sharma; Margriet M Sitskoorn; Stephanie L Rock; Sandra Woolson; Mauricio Tohen; Gary D Tollefson; Todd M Sanger; Jeffrey A Lieberman
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Biological psychiatry 2006;59(2):97-105.
2006: Matthew Hoptman; Jan Volavka; Pal Czobor; Guido Gerig; Miranda Chakos; Joseph Blocher; Leslie Citrome; Brian Sheitman; Jean-Pierre Lindenmayer; Jeffrey A Lieberman; Robert Bilder
Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder.
The Journal of neuropsychiatry and clinical neurosciences 2006;18(4):509-15.
2006: A Chistina Grobin; Samantha S Gizerian; Jeffrey A Lieberman; A Leslie Morrow
Perinatal allopregnanolone influences prefrontal cortex structure, connectivity and behavior in adult rats.
Neuroscience 2006;138(3):809-19.
2006: Leisa A Glantz; John Gilmore; Jeffrey A Lieberman; L Fredrik Jarskog
Apoptotic mechanisms and the synaptic pathology of schizophrenia.
Schizophrenia research 2006;81(1):47-63.
2005: Donald C Goff; Lisa M Sullivan; Joseph P McEvoy; Jonathan M Meyer; Henry A Nasrallah; Gail L Daumit; Steven Lamberti; Ralph B D'Agostino; Thomas Stroup; Sonia M Davis; Jeffrey A Lieberman
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.
Schizophrenia research 2005;80(1):45-53.
2005: Joseph P McEvoy; Jonathan M Meyer; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Lisa Sullivan; Herbert Y Meltzer; John K Hsiao; T Scott Stroup; Jeffrey A Lieberman
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Schizophrenia research 2005;80(1):19-32.
2005: Jonathan M Meyer; Henry A Nasrallah; Joseph P McEvoy; Donald C Goff; Sonia M Davis; Miranda Chakos; Jayendra K Patel; Richard S E Keefe; Thomas Stroup; Jeffrey A Lieberman
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
Schizophrenia research 2005;80(1):9-18.
2005: Matthew Hoptman; Jan Volavka; Elisabeth M Weiss; Pal Czobor; Philip Szeszko; Guido Gerig; Miranda Chakos; Joseph Blocher; Leslie Citrome; Jean-Pierre Lindenmayer; Brian Sheitman; Jeffrey A Lieberman; Robert Bilder
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder.
Psychiatry research 2005;140(2):133-45.
2005: Charles Nemeroff; Jeffrey A Lieberman; Peter Weiden; Philip D Harvey; John W Newcomer; Alan F Schatzberg; Clinton D Kilts; David G Daniel
From clinical research to clinical practice: a 4-year review of ziprasidone.
CNS spectrums 2005;10(11 Suppl 17):1-20.
2005: R Grant Steen; Robert M Hamer; Jeffrey A Lieberman
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(11):1949-62.
2005: Stephen M Strakowski; Jacqueline Johnson; Melissa P DelBello; Robert M Hamer; Alan I Green; Mauricio Tohen; Jeffrey A Lieberman; Ira D Glick; Jayendra K Patel
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.
Schizophrenia research 2005;78(2-3):161-9.
2005: Handan Gunduz-Bruce; Marjorie McMeniman; Delbert Robinson; Margaret G Woerner; John M Kane; Nina R Schooler; Jeffrey A Lieberman
Duration of untreated psychosis and time to treatment response for delusions and hallucinations.
The American journal of psychiatry 2005;162(10):1966-9.
2005: Diana O Perkins; Hongbin Gu; Kalina Boteva; Jeffrey A Lieberman
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.
The American journal of psychiatry 2005;162(10):1785-804.
2005: Jeffrey A Lieberman; Thomas Stroup; Joseph P McEvoy; Marvin Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne B Severe; John K Hsiao
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
The New England journal of medicine 2005;353(12):1209-23.
2005: Odin van der Stelt; Jeffrey A Lieberman; Aysenil Belger
Auditory P300 in high-risk, recent-onset and chronic schizophrenia.
Schizophrenia research 2005;77(2-3):309-20.
2005: Karen A Graham; Hongbin Gu; Jeffrey A Lieberman; Joyce B Harp; Diana O Perkins
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
The American journal of psychiatry 2005;162(9):1744-6.
2005: Jan Volavka; Karen A Nolan; Linda Kline; Pal Czobor; Leslie Citrome; Brian Sheitman; Jean-Pierre Lindenmayer; Joseph McEvoy; Jeffrey A Lieberman
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Schizophrenia research 2005;76(1):127-9.
2005: L Fredrik Jarskog; Leisa A Glantz; John Gilmore; Jeffrey A Lieberman
Apoptotic mechanisms in the pathophysiology of schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry 2005;29(5):846-58.
2005: Jeffrey A Lieberman; Gary Tollefson; Cecil Charles; Robert Zipursky; Tonmoy Sharma; Rene S Kahn; Richard S E Keefe; Alan I Green; Raquel E Gur; Joseph McEvoy; Diana O Perkins; Robert M Hamer; Hongbin Gu; Mauricio Tohen
Antipsychotic drug effects on brain morphology in first-episode psychosis.
Archives of general psychiatry 2005;62(4):361-70.
2005: Martin Styner; Jeffrey A Lieberman; Robert McClure; Daniel R Weinberger; Douglas W Jones; Guido Gerig
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(13):4872-7.
2005: Miranda Chakos; Scott A Schobel; Hongbin Gu; Guido Gerig; Daniel Bradford; Cecil Charles; Jeffrey A Lieberman
Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia.
The British journal of psychiatry : the journal of mental science 2005;186():26-31.
2005: Karen A Graham; Diana O Perkins; Lloyd J Edwards; Robert C Barrier; Jeffrey A Lieberman; Joyce B Harp
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.
The American journal of psychiatry 2005;162(1):118-23.
2005: Karen A Nolan; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Jeffrey A Lieberman
Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.
Journal of psychiatric research 2005;39(1):109-15.
2005: S Miyamoto; Gary E Duncan; Christine E Marx; Jeffrey A Lieberman
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
Molecular psychiatry 2005;10(1):79-104.
2004: Odin van der Stelt; Aysenil Belger; Jeffrey A Lieberman
Macroscopic fast neuronal oscillations and synchrony in schizophrenia.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(51):17567-8.
2004: Seiya Miyamoto; John N Snouwaert; Beverly H Koller; Sheryl S Moy; Jeffrey A Lieberman; Gary E Duncan
Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(12):2180-8.
2004: Martin Styner; Jeffrey A Lieberman; Dimitrios Pantazis; Guido Gerig
Boundary and medial shape analysis of the hippocampus in schizophrenia.
Medical image analysis 2004;8(3):197-203.
2004: Gary E Duncan; Sheryl S Moy; Antonio Perez; Dawn M Eddy; Wendy M Zinzow; Jeffrey A Lieberman; John N Snouwaert; Beverly H Koller
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function.
Behavioural brain research 2004;153(2):507-19.
2004: Samantha S Gizerian; A Leslie Morrow; Jeffrey A Lieberman; A Chistina Grobin
Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats.
Brain research 2004;1012(1-2):66-74.
2004: Richard S E Keefe; Larry J Seidman; Bruce K Christensen; Robert M Hamer; Tonmoy Sharma; Margriet M Sitskoorn; Richard R J Lewine; Deborah A Yurgelun-Todd; Ruben C Gur; Mauricio Tohen; Gary D Tollefson; Todd M Sanger; Jeffrey A Lieberman
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
The American journal of psychiatry 2004;161(6):985-95.
2004: Jan Volavka; James L Kennedy; Xingqun Ni; Pal Czobor; Karen A Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Jeffrey A Lieberman
COMT158 polymorphism and hostility.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2004;127B(1):28-9.
2004: A Chistina Grobin; Jeffrey A Lieberman; A Leslie Morrow
Perinatal flunitrazepam exposure causes persistent alteration of parvalbumin-immunoreactive interneuron localization in rat prefrontal cortex.
Neuroscience letters 2004;359(1-2):9-12.
2004: Jan Volavka; Pal Czobor; Karen A Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Jeffrey A Lieberman
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Journal of clinical psychopharmacology 2004;24(2):225-8.
2004: Odin van der Stelt; Jeremy Frye; Jeffrey A Lieberman; Aysenil Belger
Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia.
Archives of general psychiatry 2004;61(3):237-48.
2004: Sayed S Alamy; L Fredrik Jarskog; Brian Sheitman; Jeffrey A Lieberman
Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features.
Schizophrenia research 2004;66(2-3):183-6.
2004: Alan I Green; Mauricio Tohen; Robert M Hamer; Stephen M Strakowski; Jeffrey A Lieberman; Ira D Glick; W Scott Clark
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Schizophrenia research 2004;66(2-3):125-35.
2004: Thomas Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Revised PORT recommendations.
Schizophrenia bulletin 2004;30(3):609-11.
2004: Jeffrey A Lieberman
Dopamine partial agonists: a new class of antipsychotic.
CNS drugs 2004;18(4):251-67.
2004: L Fredrik Jarskog; Elzbieta S Selinger; Jeffrey A Lieberman; John Gilmore
Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation.
The American journal of psychiatry 2004;161(1):109-15.
2004: Linmarie Sikich; Robert M Hamer; Robert Bashford; Brian Sheitman; Jeffrey A Lieberman
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(1):133-45.
2003: Thomas M Maynard; Gloria T Haskell; A Z Peters; Linmarie Sikich; Jeffrey A Lieberman; Anthony-Samuel LaMantia
A comprehensive analysis of 22q11 gene expression in the developing and adult brain.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(24):14433-8.
2003: Philip Szeszko; Faith Gunning-Dixon; Robert S Goldman; John Bates; Manzar Ashtari; Peter J Snyder; Jeffrey A Lieberman; Robert Bilder
Lack of normal association between cerebellar volume and neuropsychological functions in first-episode schizophrenia.
The American journal of psychiatry 2003;160(10):1884-7.
2003: Margaret G Woerner; Delbert Robinson; Jose Alvir; Brian Sheitman; Jeffrey A Lieberman; John M Kane
Clozapine as a first treatment for schizophrenia.
The American journal of psychiatry 2003;160(8):1514-6.
2003: Jeffrey A Lieberman; Gary Tollefson; Mauricio Tohen; Alan I Green; Raquel E Gur; Rene Kahn; Joseph McEvoy; Diana O Perkins; Tonmoy Sharma; Robert Zipursky; Hank Wei; Robert M Hamer
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
The American journal of psychiatry 2003;160(8):1396-404.
2003: Gary E Duncan; Seiya Miyamoto; Jeffrey A Lieberman
Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation.
The Journal of pharmacology and experimental therapeutics 2003;305(3):999-1005.
2003: Jeffrey A Lieberman; Michael Phillips; Hongbin Gu; Scott Stroup; Peiyan Zhang; Lan Kong; Zhongfu Ji; Gary G Koch; Robert M Hamer
Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(5):995-1003.
2003: A Chistina Grobin; Erin J Heenan; Jeffrey A Lieberman; A Leslie Morrow
Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2003;23(5):1832-9.
2003: Todd Lencz; Robert Bilder; Elihu Turkel; Robert S Goldman; Delbert Robinson; John M Kane; Jeffrey A Lieberman
Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia.
Archives of general psychiatry 2003;60(3):238-43.
2003: Daniel W Bradford; Diana O Perkins; Jeffrey A Lieberman
Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.
Drugs 2003;63(21):2265-83.
2003: Thomas Stroup; Joseph P McEvoy; Marvin Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
Schizophrenia bulletin 2003;29(1):15-31.
2003: Jeffrey A Lieberman; Thomas Stroup
Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care?
Schizophrenia bulletin 2003;29(1):1-6.
2003: Christine E Marx; Margaret VanDoren; Gary E Duncan; Jeffrey A Lieberman; A Leslie Morrow
Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(1):1-13.
2002: Robert Bilder; Jan Volavka; Pal Czobor; Anil Malhotra; James L Kennedy; Xingqun Ni; Robert S Goldman; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Jeffrey A Lieberman
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia.
Biological psychiatry 2002;52(7):701-7.
2002: Delbert Robinson; Margaret G Woerner; Jose Alvir; Robert Bilder; Gregory A Hinrichsen; Jeffrey A Lieberman
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.
Schizophrenia research 2002;57(2-3):209-19.
2002: Candace Andersson; Robert M Hamer; Cindy P Lawler; Richard B Mailman; Jeffrey A Lieberman
Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;27(2):143-51.
2002: Thomas M Maynard; Gloria T Haskell; Jeffrey A Lieberman; Anthony-Samuel LaMantia
22q11 DS: genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 2002;20(3-5):407-19.
2002: Rita Z Goldstein; Tania Giovannetti; Mathew Schullery; Paula A Zuffante; Jeffrey A Lieberman; Delbert Robinson; William B Barr; Robert Bilder
Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia.
Neuropsychiatry, neuropsychology, and behavioral neurology 2002;15(2):88-98.
2002: Robert Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
The American journal of psychiatry 2002;159(6):1018-28.
2002: Pal Czobor; Jan Volavka; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Antipsychotic-induced weight gain and therapeutic response: a differential association.
Journal of clinical psychopharmacology 2002;22(3):244-51.
2002: Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
The American journal of psychiatry 2002;159(2):255-62.
2002: Philip Szeszko; Rael D Strous; Robert S Goldman; Manzar Ashtari; Kevin Knuth; Jeffrey A Lieberman; Robert Bilder
Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia.
The American journal of psychiatry 2002;159(2):217-26.
2002: Thomas M Maynard; Gloria T Haskell; Naina Bhasin; James M Lee; Andrew A Gassman; Jeffrey A Lieberman; Anthony-Samuel LaMantia
RanBP1, a velocardiofacial/DiGeorge syndrome candidate gene, is expressed at sites of mesenchymal/epithelial induction.
Mechanisms of development 2002;111(1-2):177-80.
2002: Josephine M Johns; Deborah A Lubin; Jeffrey A Lieberman; Jean M Lauder
Developmental effects of prenatal cocaine exposure on 5-HT1A receptors in male and female rat offspring.
Developmental neuroscience 2002;24(6):522-30.
2001: Jeffrey A Lieberman; Diana O Perkins; Aysenil Belger; Miranda Chakos; F Jarskog; Kalina Boteva; John Gilmore
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches.
Biological psychiatry 2001;50(11):884-97.
2001: Christine E Marx; L Fredrik Jarskog; Jean M Lauder; Jeffrey A Lieberman; John Gilmore
Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia.
Biological psychiatry 2001;50(10):743-9.
2001: Leslie Citrome; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Joseph McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Psychiatric services (Washington, D.C.) 2001;52(11):1510-4.
2001: S Miyamoto; Richard B Mailman; Jeffrey A Lieberman; Gary E Duncan
Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors.
Brain research 2001;894(2):167-80.
2001: A Urakubo; L Fredrik Jarskog; Jeffrey A Lieberman; John Gilmore
Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain.
Schizophrenia research 2001;47(1):27-36.
2001: Lon S Schneider; Pierre N. Tariot; Constantine G Lyketsos; Karen S Dagerman; Kenneth L Davis; Sonia M Davis; John K Hsiao; D V Jeste; Ira R Katz; Jason T Olin; B G Pollock; Peter V Rabins; Robert A Rosenheck; Gary W Small; Barry D Lebowitz; Jeffrey A Lieberman
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2001;9(4):346-60.
2001: Thomas M Maynard; Linmarie Sikich; Jeffrey A Lieberman; Anthony-Samuel LaMantia
Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia.
Schizophrenia bulletin 2001;27(3):457-76.
2001: Jeffrey A Lieberman
Hypothesis and hypothesis testing in the clinical trial.
The Journal of clinical psychiatry 2001;62 Suppl 9():5-8; discussion 9-10.
2000: Brian Sheitman; M G Murray; J A Snyder; S Silva; R Goldman; Miranda Chakos; Jan Volavka; Jeffrey A Lieberman
IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness.
Schizophrenia research 2000;46(2-3):203-7.
2000: Daniel C Javitt; AM Shelley; Gail Silipo; Jeffrey A Lieberman
Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern.
Archives of general psychiatry 2000;57(12):1131-7.
2000: L Fredrik Jarskog; John Gilmore; Elzbieta S Selinger; Jeffrey A Lieberman
Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia.
Biological psychiatry 2000;48(7):641-50.
2000: Jeffrey A Lieberman; R Golden; Scott Stroup; Joseph McEvoy
Drugs of the psychopharmacological revolution in clinical psychiatry.
Psychiatric services (Washington, D.C.) 2000;51(10):1254-8.
2000: Christine E Marx; L Fredrik Jarskog; Jean M Lauder; John Gilmore; Jeffrey A Lieberman; A Leslie Morrow
Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia.
Brain research 2000;871(1):104-12.
2000: Diana O Perkins; Jane Madison; L Fredrik Jarskog; Karen A Graham; J Kazmer; Jeffrey A Lieberman
Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory.
Schizophrenia research 2000;44(1):1-10.
2000: David H Overstreet; Sheryl S Moy; Deborah A Lubin; L R Gause; Jeffrey A Lieberman; Josephine M Johns
Enduring effects of prenatal cocaine administration on emotional behavior in rats.
Physiology & behavior 2000;70(1-2):149-56.
2000: Philip Szeszko; Robert Bilder; Todd Lencz; Manzar Ashtari; Robert S Goldman; G Reiter; H Wu; Jeffrey A Lieberman
Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia.
Schizophrenia research 2000;43(2-3):97-108.
2000: Christine E Marx; Gary E Duncan; John Gilmore; Jeffrey A Lieberman; A Leslie Morrow
Olanzapine increases allopregnanolone in the rat cerebral cortex.
Biological psychiatry 2000;47(11):1000-4.
2000: L Fredrik Jarskog; Mark Mattioli; Diana O Perkins; Jeffrey A Lieberman
First-episode psychosis in a managed care setting: clinical management and research.
The American journal of psychiatry 2000;157(6):878-84.
2000: Robert Bilder; Robert S Goldman; Delbert Robinson; G Reiter; L Bell; John A Bates; E Pappadopulos; D F Willson; Jose Alvir; Margaret G Woerner; S Geisler; John M Kane; Jeffrey A Lieberman
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.
The American journal of psychiatry 2000;157(4):549-59.
2000: Gary E Duncan; Seiya Miyamoto; JN Leipzig; Jeffrey A Lieberman
Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism.
The Journal of pharmacology and experimental therapeutics 2000;293(1):8-14.
2000: Seiya Miyamoto; JN Leipzig; Jeffrey A Lieberman; Gary E Duncan
Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;22(4):400-12.
1999: Handan Gunduz; Margaret G Woerner; Jose Alvir; G Degreef; Jeffrey A Lieberman
Obstetric complications in schizophrenia, schizoaffective disorder and normal comparison subjects.
Schizophrenia research 1999;40(3):237-43.
1999: Gary E Duncan; Seiya Miyamoto; JN Leipzig; Jeffrey A Lieberman
Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine.
Brain research 1999;843(1-2):171-83.
1999: Jeffrey A Lieberman
Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective.
Biological psychiatry 1999;46(6):729-39.
1999: Jose Alvir; Margaret G Woerner; Handan Gunduz; G Degreef; Jeffrey A Lieberman
Obstetric complications predict treatment response in first-episode schizophrenia.
Psychological medicine 1999;29(3):621-7.
1999: Delbert Robinson; Margaret G Woerner; Jose Alvir; S Geisler; AR Koreen; Brian Sheitman; Miranda Chakos; David Mayerhoff; Robert Bilder; R Goldman; Jeffrey A Lieberman
Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.
The American journal of psychiatry 1999;156(4):544-9.
1999: Delbert Robinson; Margaret G Woerner; Jose Alvir; Robert Bilder; R Goldman; S Geisler; AR Koreen; Brian Sheitman; Miranda Chakos; David Mayerhoff; Jeffrey A Lieberman
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
Archives of general psychiatry 1999;56(3):241-7.
1999: Philip Szeszko; Robert Bilder; Todd Lencz; Simcha Pollack; Jose Alvir; Manzar Ashtari; H Wu; Jeffrey A Lieberman
Investigation of frontal lobe subregions in first-episode schizophrenia.
Psychiatry research 1999;90(1):1-15.
1999: Karon Dawkins; Jeffrey A Lieberman; Barry D Lebowitz; John K Hsiao
Antipsychotics: Past and Future: National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998.
Schizophrenia bulletin 1999;25(2):395-405.
1999: Richard S E Keefe; Susan G Silva; Diana O Perkins; Jeffrey A Lieberman
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
Schizophrenia bulletin 1999;25(2):201-22.
1999: Jeffrey A Lieberman
Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia.
The Journal of clinical psychiatry 1999;60 Suppl 12():9-12.
1999: H Lee; FI Tarazi; Miranda Chakos; H Wu; M Redmond; Jose Alvir; B J Kinon; Robert Bilder; I Creese; Jeffrey A Lieberman
Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum.
Life sciences 1999;64(18):1595-602.
1998: Jeffrey A Lieberman; Richard B Mailman; Gary E Duncan; Linmarie Sikich; Miranda Chakos; David E Nichols; John E Kraus
Serotonergic basis of antipsychotic drug effects in schizophrenia.
Biological psychiatry 1998;44(11):1099-117.
1998: Gary E Duncan; JN Leipzig; Richard B Mailman; Jeffrey A Lieberman
Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.
Brain research 1998;812(1-2):65-75.
1998: Margaret G Woerner; Jose Alvir; Bruce L Saltz; Jeffrey A Lieberman; John M Kane
Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
The American journal of psychiatry 1998;155(11):1521-8.
1998: Christine E Marx; Jeffrey A Lieberman
Psychoneuroendocrinology of schizophrenia.
The Psychiatric clinics of North America 1998;21(2):413-34.
1998: Brian Sheitman; Jeffrey A Lieberman
The natural history and pathophysiology of treatment resistant schizophrenia.
Journal of psychiatric research 1998;32(3-4):143-50.
1998: Jeffrey A Lieberman; Brian Sheitman; Miranda Chakos; Delbert Robinson; N Schooler; S Keith
The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective.
Journal of clinical psychopharmacology 1998;18(2 Suppl 1):20S-4S.
1998: Diana O Perkins; Jeffrey A Lieberman
Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs.
The American journal of psychiatry 1998;155(2):272-6.
1998: Miranda Chakos; S Esposito; Cecil Charles; Jeffrey A Lieberman
Clinical applications of neuroimaging in psychiatry.
Magnetic resonance imaging clinics of North America 1998;6(1):155-64.
1998: Jeffrey A Lieberman
Maximizing clozapine therapy: managing side effects.
The Journal of clinical psychiatry 1998;59 Suppl 3():38-43.
1997: Jeffrey A Lieberman; Brian Sheitman; B J Kinon
Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1997;17(4):205-29.
1997: William B Barr; Manzar Ashtari; Robert Bilder; G Degreef; Jeffrey A Lieberman
Brain morphometric comparison of first-episode schizophrenia and temporal lobe epilepsy.
The British journal of psychiatry : the journal of mental science 1997;170():515-9.
1997: Nina R Schooler; S J Keith; J B Severe; S M Matthews; Alan S Bellack; Ira D Glick; W A Hargreaves; John M Kane; P T Ninan; A Frances; M Jacobs; Jeffrey A Lieberman; R Mance; George M Simpson; Margaret G Woerner
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
Archives of general psychiatry 1997;54(5):453-63.
1997: AR Koreen; Jeffrey A Lieberman; Jose Alvir; Miranda Chakos
The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1997;16(1):61-8.
1996: M G Woerner; Brian Sheitman; Jeffrey A Lieberman; John M Kane
Tardive dyskinesia induced by risperidone?
The American journal of psychiatry 1996;153(6):843.
1996: AM Shelley; S Grochowski; Jeffrey A Lieberman; Daniel C Javitt
Premature disinhibition of P3 generation in schizophrenia.
Biological psychiatry 1996;39(8):714-9.
1996: Miranda Chakos; Jose Alvir; Margaret G Woerner; A Koreen; S Geisler; David Mayerhoff; S Sobel; John M Kane; Michael Borenstein; Jeffrey A Lieberman
Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.
Archives of general psychiatry 1996;53(4):313-9.
1996: B J Kinon; Jeffrey A Lieberman
Mechanisms of action of atypical antipsychotic drugs: a critical analysis.
Psychopharmacology 1996;124(1-2):2-34.
1996: Jeffrey A Lieberman; Jose Alvir; A Koreen; S Geisler; Miranda Chakos; Brian Sheitman; Margaret G Woerner
Psychobiologic correlates of treatment response in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(3 Suppl):13S-21S.
1996: Jeffrey A Lieberman
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.
The Journal of clinical psychiatry 1996;57 Suppl 11():68-71.
1996: Jeffrey A Lieberman; A R Koreen; Miranda Chakos; Brian Sheitman; Margaret G Woerner; Jose Alvir; Robert Bilder
Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.
The Journal of clinical psychiatry 1996;57 Suppl 9():5-9.
1995: A Chatterjee; Miranda Chakos; A Koreen; S Geisler; Brian Sheitman; Margaret G Woerner; John M Kane; Jose Alvir; Jeffrey A Lieberman
Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.
The American journal of psychiatry 1995;152(12):1724-9.
1995: Robert Bilder; B Bogerts; Manzar Ashtari; H Wu; Jose Alvir; D Jody; G Reiter; L Bell; Jeffrey A Lieberman
Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia.
Schizophrenia research 1995;17(1):47-58.
1995: S Szymanski; Jeffrey A Lieberman; Jose Alvir; David Mayerhoff; A Loebel; S Geisler; Miranda Chakos; A Koreen; D Jody; John M Kane
Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.
The American journal of psychiatry 1995;152(5):698-703.
1995: J S Aronowitz; A Z Safferman; Jeffrey A Lieberman
Management of clozapine-induced enuresis.
The American journal of psychiatry 1995;152(3):472.
1995: Miranda Chakos; Jeffrey A Lieberman; Jose Alvir; Robert Bilder; Manzar Ashtari
Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine.
Lancet 1995;345(8947):456-7.
1995: D Umbricht; G Degreef; William B Barr; Jeffrey A Lieberman; Simcha Pollack; N Schaul
Postictal and chronic psychoses in patients with temporal lobe epilepsy.
The American journal of psychiatry 1995;152(2):224-31.
1995: M H Kronig; R A Munne; S Szymanski; A Z Safferman; Simcha Pollack; T Cooper; John M Kane; Jeffrey A Lieberman
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.
The American journal of psychiatry 1995;152(2):179-82.
1995: Margaret G Woerner; Jose Alvir; John M Kane; B L Saltz; Jeffrey A Lieberman
Neuroleptic treatment of elderly patients.
Psychopharmacology bulletin 1995;31(2):333-7.
1995: Simcha Pollack; Jeffrey A Lieberman; W Wolfgang Fleischhacker; Michael Borenstein; A Z Safferman; Martina Hummer; Martin Kurz
A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects.
Psychopharmacology bulletin 1995;31(2):315-20.
1995: Jose Alvir; Jeffrey A Lieberman; A Z Safferman
Do white-cell count spikes predict agranulocytosis in clozapine recipients?
Psychopharmacology bulletin 1995;31(2):311-4.
1994: Jeffrey A Lieberman; A Z Safferman; Simcha Pollack; S Szymanski; C Johns; A Howard; M Kronig; P Bookstein; John M Kane
Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.
The American journal of psychiatry 1994;151(12):1744-52.
1994: J S Aronowitz; Miranda Chakos; A Z Safferman; Jeffrey A Lieberman
Syncope associated with the combination of clozapine and enalapril.
Journal of clinical psychopharmacology 1994;14(6):429-30.
1994: Robert Bilder; H Wu; B Bogerts; G Degreef; Manzar Ashtari; Jose Alvir; P J Snyder; Jeffrey A Lieberman
Absence of regional hemispheric volume asymmetries in first-episode schizophrenia.
The American journal of psychiatry 1994;151(10):1437-47.
1994: David Mayerhoff; A D Loebel; Jose Alvir; S R Szymanski; S H Geisler; Michael Borenstein; Jeffrey A Lieberman
The deficit state in first-episode schizophrenia.
The American journal of psychiatry 1994;151(10):1417-22.
1994: Miranda Chakos; Jeffrey A Lieberman; Robert Bilder; Michael Borenstein; G Lerner; B Bogerts; H Wu; B Kinon; Manzar Ashtari
Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs.
The American journal of psychiatry 1994;151(10):1430-6.
1994: Jeffrey A Lieberman; Jose Alvir; S Geisler; J Ramos-Lorenzi; Margaret G Woerner; H Novacenko; T Cooper; John M Kane
Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1994;11(2):107-18.
1994: A Z Safferman; John M Kane; J S Aronowitz; M F Gordon; Simcha Pollack; Jeffrey A Lieberman
The use of clozapine in neurologic disorders.
The Journal of clinical psychiatry 1994;55 Suppl B():98-101.
1994: W Wolfgang Fleischhacker; Martina Hummer; Martin Kurz; Ilsemarie Kurzthaler; Jeffrey A Lieberman; Simcha Pollack; A Z Safferman; John M Kane
Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects.
The Journal of clinical psychiatry 1994;55 Suppl B():78-81.
1994: John M Kane; A Z Safferman; Simcha Pollack; C Johns; S Szymanski; M Kronig; Jeffrey A Lieberman
Clozapine, negative symptoms, and extrapyramidal side effects.
The Journal of clinical psychiatry 1994;55 Suppl B():74-7.
1994: Robert Bilder; H Wu; Miranda Chakos; B Bogerts; Simcha Pollack; J Aronowitz; Manzar Ashtari; G Degreef; John M Kane; Jeffrey A Lieberman
Cerebral morphometry and clozapine treatment in schizophrenia.
The Journal of clinical psychiatry 1994;55 Suppl B():53-6.
1994: Jose Alvir; Jeffrey A Lieberman
Agranulocytosis: incidence and risk factors.
The Journal of clinical psychiatry 1994;55 Suppl B():137-8.
1994: Jeffrey A Lieberman; John M Kane; A Z Safferman; Simcha Pollack; A Howard; S Szymanski; S J Masiar; M H Kronig; T Cooper; H Novacenko
Predictors of response to clozapine.
The Journal of clinical psychiatry 1994;55 Suppl B():126-8.
1994: A Z Safferman; Jeffrey A Lieberman; D Zeman; S Szymanski; A V Pisciotta; Kanti Rai
Response to "Unrelated agranulocytosis in a patient taking clozapine".
Journal of clinical psychopharmacology 1994;14(3):211-2.
1993: Jeffrey A Lieberman
Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development.
The British journal of psychiatry. Supplement 1993;(22):7-18.
1993: W Wolfgang Fleischhacker; CH Miller; C Barnas; K Bergmann; R Perovich; J M Alvir; Jeffrey A Lieberman; John M Kane
The effect of activation procedures on neuroleptic-induced akathisia.
The British journal of psychiatry : the journal of mental science 1993;163():781-4.
1993: W Wolfgang Fleischhacker; R A Levine; Jeffrey A Lieberman; Simcha Pollack; C A Johns; M A Richardson
Neopterin and biopterin CSF levels in tardive dyskinesia after clozapine treatment.
Biological psychiatry 1993;34(10):741-5.
1993: D S Umbricht; B Saltz; Simcha Pollack; Margaret G Woerner; John M Kane; Jeffrey A Lieberman
Polydipsia and tardive dyskinesia in chronic psychiatric patients--related disorders?
The American journal of psychiatry 1993;150(10):1536-8.
1993: John M Kane; Margaret G Woerner; Simcha Pollack; A Z Safferman; Jeffrey A Lieberman
Does clozapine cause tardive dyskinesia?
The Journal of clinical psychiatry 1993;54(9):327-30.
1993: Jose Alvir; Jeffrey A Lieberman; A Z Safferman; J L Schwimmer; J A Schaaf
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
The New England journal of medicine 1993;329(3):162-7.
1993: A Z Safferman; Jeffrey A Lieberman; D Zeman; S Szymanski; A V Pisciotta; Kanti Rai
Unrelated agranulocytosis in a patient taking clozapine.
Journal of clinical psychopharmacology 1993;13(3):218-9.
1993: J A Selzer; Jeffrey A Lieberman
Schizophrenia and substance abuse.
The Psychiatric clinics of North America 1993;16(2):401-12.
1993: Margaret G Woerner; B L Saltz; John M Kane; Jeffrey A Lieberman; Jose Alvir
Diabetes and development of tardive dyskinesia.
The American journal of psychiatry 1993;150(6):966-8.
1993: Jeffrey A Lieberman; D Jody; Jose Alvir; Manzar Ashtari; Deborah L Levy; B Bogerts; G Degreef; David Mayerhoff; T Cooper
Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates.
Archives of general psychiatry 1993;50(5):357-68.
1993: S Szymanski; Jeffrey A Lieberman; A Safferman; B Galkowski
Rib fractures as an unusual complication of severe tardive dystonia.
The Journal of clinical psychiatry 1993;54(4):160.
1993: Jeffrey A Lieberman
Prediction of outcome in first-episode schizophrenia.
The Journal of clinical psychiatry 1993;54 Suppl():13-7.
1993: B Bogerts; Jeffrey A Lieberman; Manzar Ashtari; Robert Bilder; G Degreef; G Lerner; C Johns; S Masiar
Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia.
Biological psychiatry 1993;33(4):236-46.
1993: Jeffrey A Lieberman; A R Koreen
Neurochemistry and neuroendocrinology of schizophrenia: a selective review.
Schizophrenia bulletin 1993;19(2):371-429.
1992: Deborah L Levy; B Bogerts; G Degreef; B Dorogusker; C Waternaux; Manzar Ashtari; D Jody; S Geisler; Jeffrey A Lieberman
Normal eye tracking is associated with abnormal morphology of medial temporal lobe structures in schizophrenia.
Schizophrenia research 1992;8(1):1-10.
1992: A D Loebel; Jeffrey A Lieberman; Jose Alvir; David Mayerhoff; S H Geisler; S R Szymanski
Duration of psychosis and outcome in first-episode schizophrenia.
The American journal of psychiatry 1992;149(9):1183-8.
1992: G Degreef; Manzar Ashtari; B Bogerts; Robert Bilder; D N Jody; Jose Alvir; Jeffrey A Lieberman
Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients.
Archives of general psychiatry 1992;49(7):531-7.
1992: A Z Safferman; Jeffrey A Lieberman; Jose Alvir; A Howard
Rechallenge in clozapine-induced agranulocytosis.
Lancet 1992;339(8804):1296-7.
1992: Miranda Chakos; David Mayerhoff; A D Loebel; Jose Alvir; Jeffrey A Lieberman
Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
Psychopharmacology bulletin 1992;28(1):81-6.
1992: Jeffrey A Lieberman; Jose Alvir
A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors.
Drug safety : an international journal of medical toxicology and drug experience 1992;7 Suppl 1():1-2.
1992: B Bogerts; Jeffrey A Lieberman; Robert Bilder; Manzar Ashtari; G Degreef; G Lerner; C Johns; S Masiar
A volumetric MRI study of limbic structures in chronic schizophrenia--relationship to psychopathology.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():112A-113A.
1992: Jeffrey A Lieberman; A Z Safferman
Clinical profile of clozapine: adverse reactions and agranulocytosis.
The Psychiatric quarterly 1992;63(1):51-70.
1992: Robert Bilder; L Lipschutz-Broch; G Reiter; S H Geisler; David Mayerhoff; Jeffrey A Lieberman
Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration.
Schizophrenia bulletin 1992;18(3):437-48.
1992: Jeffrey A Lieberman; Jose Alvir; Margaret G Woerner; G Degreef; Robert Bilder; Manzar Ashtari; B Bogerts; David Mayerhoff; S H Geisler; A Loebel
Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital.
Schizophrenia bulletin 1992;18(3):351-71.
1992: Robert Bilder; Elihu Turkel; L Lipschutz-Broch; Jeffrey A Lieberman
Antipsychotic medication effects on neuropsychological functions.
Psychopharmacology bulletin 1992;28(4):353-66.
1991: B L Saltz; Margaret G Woerner; John M Kane; Jeffrey A Lieberman; Jose Alvir; K J Bergmann; K Blank; J Koblenzer; K Kahaner
Prospective study of tardive dyskinesia incidence in the elderly.
JAMA : the journal of the American Medical Association 1991;266(17):2402-6.
1991: Robert Bilder; L Lipschutz-Broch; G Reiter; S Geisler; David Mayerhoff; Jeffrey A Lieberman
Neuropsychological deficits in the early course of first episode schizophrenia.
Schizophrenia research 1991;5(3):198-9.
1991: C Z Lemus; Jeffrey A Lieberman; C A Johns; David Mayerhoff; Simcha Pollack; T B Cooper; H Novacenko
Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients.
Biological psychiatry 1991;29(7):691-4.
1991: Jeffrey A Lieberman; B L Saltz; C A Johns; S Pollack; Michael Borenstein; John M Kane
The effects of clozapine on tardive dyskinesia.
The British journal of psychiatry : the journal of mental science 1991;158():503-10.
1991: Margaret G Woerner; John M Kane; Jeffrey A Lieberman; Jose Alvir; K J Bergmann; Michael Borenstein; Nina R Schooler; S Mukherjee; J Rotrosen; M Rubinstein
The prevalence of tardive dyskinesia.
Journal of clinical psychopharmacology 1991;11(1):34-42.
1991: S Szymanski; Jeffrey A Lieberman; D Picou; S Masiar; T Cooper
A case report of cimetidine-induced clozapine toxicity.
The Journal of clinical psychiatry 1991;52(1):21-2.
1991: A Safferman; Jeffrey A Lieberman; John M Kane; S Szymanski; B Kinon
Update on the clinical efficacy and side effects of clozapine.
Schizophrenia bulletin 1991;17(2):247-61.
1991: S Szymanski; John M Kane; Jeffrey A Lieberman
A selective review of biological markers in schizophrenia.
Schizophrenia bulletin 1991;17(1):99-111.
1990: Jeffrey A Lieberman; J Yunis; E Egea; R T Canoso; John M Kane; E J Yunis
HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia.
Archives of general psychiatry 1990;47(10):945-8.
1990: David Mayerhoff; Jeffrey A Lieberman; C Z Lemus; Simcha Pollack; B S Schneider
Growth hormone response to growth hormone-releasing hormone in schizophrenic patients.
The American journal of psychiatry 1990;147(8):1072-4.
1990: C Z Lemus; Jeffrey A Lieberman; C A Johns; Simcha Pollack; P Bookstein; T B Cooper
CSF 5-hydroxyindoleacetic acid levels and suicide attempts in schizophrenia.
Biological psychiatry 1990;27(8):926-9.
1990: B Bogerts; Manzar Ashtari; G Degreef; Jose Alvir; Robert Bilder; Jeffrey A Lieberman
Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia.
Psychiatry research 1990;35(1):1-13.
1990: Jeffrey A Lieberman; M B Bowers
Substance abuse comorbidity in schizophrenia: editors' introduction.
Schizophrenia bulletin 1990;16(1):29-30.
1990: D Jody; Jeffrey A Lieberman; S Geisler; S Szymanski; Jose Alvir
Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia.
Psychopharmacology bulletin 1990;26(2):224-30.
1990: Jose Alvir; Jeffrey A Lieberman; Michael Borenstein
A single estimate of separate within-individual correlations: applications in psychopharmacology.
Psychopharmacology bulletin 1990;26(2):203-6.
1990: Jeffrey A Lieberman; B J Kinon; A D Loebel
Dopaminergic mechanisms in idiopathic and drug-induced psychoses.
Schizophrenia bulletin 1990;16(1):97-110.
1989: R M Perovich; Jeffrey A Lieberman; W Wolfgang Fleischhacker; Jose Alvir
The behavioral toxicity of bromocriptine in patients with psychiatric illness.
Journal of clinical psychopharmacology 1989;9(6):417-22.
1989: Jeffrey A Lieberman; Jose Alvir; S Mukherjee; John M Kane
Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy.
Archives of general psychiatry 1989;46(10):908-13.
1989: Jeffrey A Lieberman; John M Kane; C A Johns
Clozapine: guidelines for clinical management.
The Journal of clinical psychiatry 1989;50(9):329-38.
1989: Jeffrey A Lieberman; B L Saltz; C A Johns; Simcha Pollack; John M Kane
Clozapine effects on tardive dyskinesia.
Psychopharmacology bulletin 1989;25(1):57-62.
1989: B L Saltz; John M Kane; Margaret G Woerner; Jeffrey A Lieberman; Jose Alvir; K Blank; K Kahaner; Carmel Foley
Prospective study of tardive dyskinesia in the elderly.
Psychopharmacology bulletin 1989;25(1):52-6.
1989: W Wolfgang Fleischhacker; K J Bergmann; R Perovich; L K Pestreich; Michael Borenstein; Jeffrey A Lieberman; John M Kane
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia.
Psychopharmacology bulletin 1989;25(2):222-6.
1989: C Z Lemus; Jeffrey A Lieberman; C A Johns
Myoclonus during treatment with clozapine and lithium: the role of serotonin.
The Hillside journal of clinical psychiatry 1989;11(2):127-30.
1988: Jeffrey A Lieberman; C A Johns; John M Kane; Kanti Rai; A V Pisciotta; B L Saltz; A Howard
Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs.
The Journal of clinical psychiatry 1988;49(7):271-7.
1987: Jeffrey A Lieberman; John M Kane; S Sarantakos; D Gadaleta; Margaret G Woerner; Jose Alvir; J Ramos-Lorenzi
Prediction of relapse in schizophrenia.
Archives of general psychiatry 1987;44(7):597-603.
1986: Jeffrey A Lieberman; John M Kane; S Sarantakos; D Gadaletta; Margaret G Woerner; Jose Alvir; J Ramos-Lorenzi
Prediction of relapse in schizophrenia.
Psychopharmacology bulletin 1986;22(3):845-53.
1985: Jeffrey A Lieberman; John M Kane; S Sarantakos; K Cole; A Howard; Michael Borenstein; H Novacenko; J Puig-Antich
Dexamethasone suppression tests in patients with obsessive-compulsive disorder.
The American journal of psychiatry 1985;142(6):747-51.
1985: Jeffrey A Lieberman; John M Kane; D Gadaletta; J Ramos-Lorenzi; K Bergmann; J Wegner; H Novacenko
Methylphenidate challenge tests and course of schizophrenia.
Psychopharmacology bulletin 1985;21(1):123-9.